Browsing by Author "Arendrup, Maiken Cavling"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ECMM CandiReg - A ready to use platform for outbreaks and epidemiological studiesPublication . Koehler, Philipp; Arendrup, Maiken Cavling; Arikan‐Akdagli, Sevtap; Bassetti, Matteo; Bretagne, Stéphane; Klingspor, Lena; Lagrou, Katrien; Meis, Jacques F.; Rautemaa‐Richardson, Riina; Schelenz, Silke; Hamprecht, Axel; Koehler, Felix C.; Kurzai, Oliver; Salmanton‐García, Jon; Vehreschild, Jörg‐Janne; Alanio, Alexandre; Alastruey‐Izquierdo, Ana; Arsic Arsenijevic, Valentina; Gangneux, Jean‐Pierre; Gow, Neil A. R.; Hadina, Suzana; Hamal, Petr; Johnson, Elizabeth; Klimko, Nikolay; Lass‐Flörl, Cornelia; Mares, Mihai; Özenci, Volkan; Papp, Tamas; Roilides, Emmanuel; Sabino, Raquel; Segal, Esther; Talento, Alida Fe; Tortorano, Anna Maria; Verweij, Paul E.; Hoenigl, Martin; Cornely, Oliver A.; European Confederation of Medical Mycology (ECMM)Background: Recent outbreaks of Candida auris further exemplify that invasive Candida infections are a substantial threat to patients and healthcare systems. Even short treatment delays are associated with higher mortality rates. Epidemiological shifts towards more resistant Candida spp. require careful surveillance. Objectives: Triggered by the emergence of C auris and by increasing antifungal resistance rates the European Confederation of Medical Mycology developed an international Candida Registry (FungiScope™ CandiReg) to allow contemporary multinational surveillance. Methods: CandiReg serves as platform for international cooperation to enhance research regarding invasive Candida infections. CandiReg uses the General Data Protection Regulation compliant data platform ClinicalSurveys.net that holds the electronic case report forms (eCRF). Data entry is supported via an interactive macro created by the software that can be accessed via any Internet browser. Results: CandiReg provides an eCRF for invasive Candida infections that can be used for a variety of studies from cohort studies on attributable mortality to evaluations of guideline adherence, offering to the investigators of the 28 ECMM member countries the opportunity to document their cases of invasive Candida infection. CandiReg allows the monitoring of epidemiology of invasive Candida infections, including monitoring of multinational outbreaks. Here, we describe the structure and management of the CandiReg platform. Conclusion: CandiReg supports the collection of clinical information and isolates to improve the knowledge on epidemiology and eventually to improve management of invasive Candida infections. CandiReg promotes international collaboration, improving the availability and quality of evidence on invasive Candida infection and contributes to improved patient management.
- Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP‐EBMT, EORTC‐IDG and SEIFEM surveyPublication . Lanternier, Fanny; Seidel, Danila; Pagano, Livio; Styczynski, Jan; Mikulska, Malgorzata; Pulcini, Celine; Maertens, Johan; Munoz, Patricia; Garcia‐Vidal, Carol; Rijnders, Bart; Arendrup, Maiken Cavling; Sabino, Raquel; Verissimo, Cristina; Gaustad, Peter; Klimko, Nikolay; Arikan‐Akdagli, Sevtap; Arsic, Valentina; Barac, Aleksandra; Skiada, Anna; Klingspor, Lena; Herbrecht, Raoul; Donnelly, Peter; Cornely, Oliver A.; Lass‐Flörl, Cornelia; Lortholary, OlivierInvasive pulmonary aspergillosis (IPA) optimal duration of antifungal treatment is not known. In a joint effort, four international scientific societies/groups performed a survey to capture current practices in European haematology centres regarding management of IPA. We conducted a cross-sectional internet-based questionnaire survey in 2017 to assess practices in sixteen European countries concerning IPA management in haematology patients including tools to evaluate treatment response, duration and discontinuation. The following four groups/societies were involved in the project: European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG), Infectious Diseases Working Party-European Society for Blood and Bone Marrow Transplantation (IDWP-EBMT), European Organisation for Research and Treatment-Infectious Disease group (EORTC-IDG) and Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM). A total of 112 physicians from 14/16 countries answered the survey. Galactomannan antigen was available in serum and bronchoalveolar lavage in most centres (106/112 [95%] and 97/112 [87%], respectively), quantitative Aspergillus PCR in 27/112 (24%) centres, β-D-glucan in 24/112 (21%) and positron emission tomography in 50/112 (45%). Treatment duration differed between haematological malignancies, with a median duration of 6 weeks [IQR 3-12] for patients with AML, 11 [4-12] for patients with allogenic stem cell transplantation and GvHD and 6 [3-12] for patients with lymphoproliferative disease. Treatment duration significantly differed according to country. Essential IPA biomarkers are not available in all European countries, and treatment duration is highly variable according to country. It will be important to provide guidelines to help with IPA treatment cessation with algorithms according to biomarker availability.